Immix Biopharma, Inc. (IMMX) Research
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Market snapshot
- Symbol
- IMMX
- Price
- $8.72
- Day change
- -4.49%
- Market cap
- $474.4M
- P/E ratio
- -9.54x
- 52-week range
- 1.94-11.61
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $17.00
Recent news
- Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
Peer companies
Recent insider activity
- Adams Helen C. — A-Award (6250 shares) on 2026-05-22
- Adams Helen C. — A-Award (12500 shares) on 2026-05-22
- Ng Carey — A-Award (6250 shares) on 2026-05-22
- Ng Carey — A-Award (12500 shares) on 2026-05-22
- Marquet Magda — A-Award (6250 shares) on 2026-05-22
Open Immix Biopharma, Inc. (IMMX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.